programmed death 1 pd 1 receptor clinical trial intelligence

Phase 4, Open Label, Non-comparative, Interventional, Multicenter Study to Evaluate the Safety of Dostarlimab in Adult Patients in India With Mismatch Repair Deficient (dMMR)/Microsatellite Instability-high (MSI-H) Recurrent or Advanced Endometrial Cancer (EC) That Has Progressed on or Following Prior Treatment With a Platinum-containing Regimen

Dostarlimab, a PD-1 inhibitor, is being evaluated for safety in adult patients with dMMR/MSI-H recurrent or advanced endometrial cancer in India. This study addresses a significant unmet need in a population with limited treatment options following platinum-based therapies. The trial's multicenter design may facilitate broader patient recruitment, enhancing GSK's market presence in oncology within the region. Given the increasing prevalence of endometrial cancer and the growing acceptance of immunotherapies, successful outcomes could position GSK favorably against competitors in the PD-1 inhibitor space, particularly in emerging markets. The trial's initiation in mid-2025 aligns with GSK's strategic focus on expanding its oncology portfolio.

Matched by target_normalized: Programmed Death-1 (PD-1) receptor